{"filings":[{"id":104133,"accession_number":"0001493152-26-011755","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Bioxytran completes $1.2M private placement, issues 21.1M shares and 19.8M warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $1.2 million from sale of 21,071,667 shares at $0.055 per share.","Warrants issued to purchase up to 19,750,001 shares at $0.12 per share, exercisable immediately for five years.","Net proceeds to fund working capital, development programs, and commercialization of A-SUQAR dietary supplement.","Transaction closed March 18, 2026; securities sold to accredited investors under Regulation D exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104132,"accession_number":"0001493152-26-010045","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["3.03","5.02","5.03","9.01"],"status":"ready","headline":"Bioxytran amends preferred stock conversion rights, grants CEO 6M preferred shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment requires both Board and majority of Preferred holders to approve any conversion of Convertible Preferred Stock into common shares.","Filing effective Feb 18, 2026 with Nevada Secretary of State.","CEO David Platt granted 6,000,000 shares of Convertible Preferred Stock as performance-based equity award.","Grant tied to execution of first commercial distribution agreement and capital funding initiatives.","Aligns executive incentives with commercialization and capital formation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104131,"accession_number":"0001493152-26-008475","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran's ProLectin-M achieves 90% Day-5 viral clearance in Phase 1b/2a COVID-19 study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b/2a trial: 39 patients; highest dose 16,800 mg/day showed 90% Day-5 viral clearance vs 20% placebo (p=0.001).","90% of highest-dose cohort had ≥2-point improvement on WHO Ordinal Scale by Day 5 vs 20% placebo.","No serious adverse events, no treatment-related discontinuations; favorable safety profile across all doses.","ProLectin-M targets galectins to block viral entry; potential broad-range antiviral beyond COVID-19.","Company plans larger studies to evaluate ProLectin-M as first-line oral antiviral therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104130,"accession_number":"0001493152-26-006891","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bioxytran signs distribution deal with Khoury Medical for A-SUQAR supplement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Khoury Medical to commercialize A-SUQAR, a chewable blood sugar supplement using Bioxytran's PHGG formulation.","CEO David Platt says deal marks transition from development-stage to recurring commercial revenue while preserving IP ownership.","Volume-based marketplace exclusivity possible if defined purchase thresholds are met, per agreement terms.","Initial commercial shipments expected after completion of standard launch preparations; manufacturing by Bioxytran's OEM.","Bioxytran retains full IP; deal applies only to non-pharmaceutical dietary products, preserving pharma/antiviral programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104129,"accession_number":"0001493152-26-006081","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).","No viral rebounds observed during the 14-day post-treatment observation period.","16 of 38 subjects had non-detection by Day 5; 1 of 38 by Day 3.","Phase 2 dose-optimization trial: randomized, double-blind, 38 subjects completed.","Company plans regulatory discussions for late-stage development and additional viral indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104128,"accession_number":"0001493152-26-000418","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bioxytran terminates Officer Mike Sheikh; Sheikh contests dismissal reason affecting severance","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Mike Sheikh terminated as an Officer effective December 29, 2025.","Sheikh sent letter on December 31, 2025 contesting reason for dismissal.","Contest outcome will determine if any severance benefits are paid.","No replacement officer named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120397,"accession_number":"0001493152-25-027639","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director resigns citing governance concerns; Bioxytran hires independent expert for controls review","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anders Utter resigns from Bioxytran's Board and Audit Committee chair, effective Dec 7, 2025, citing need for enhanced oversight and controls.","Utter's recommendations included strengthening segregation of duties, improving financial approval documentation, and legal review of a recent stock issuance.","Company engages an independent third-party financial expert to review oversight, internal controls, and approval processes.","No disagreement related to financial statements, accounting practices, or SEC disclosures, per filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154247,"accession_number":"0001641172-25-002602","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K/A","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bioxytran acquires NDPD Pharma in $15.85M stock deal; CFO adopts 10b5-1 plan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of NDPD Pharma for 3,389,169 common shares and 28,467,564 preferred shares valued at ~$12.46M.","NDPD held patents for PLM (PHGG) to treat COVID-19 and 60+ viruses; appraised asset value $15.85M including license.","Related-party accounting (ASC 805-50) requires purchase price of $12.47M to be eliminated against equity, not recorded as assets.","CFO Ola Soderquist adopted a 10b5-1 plan to sell up to 500,000 shares by Dec 31, 2025, contingent on price thresholds.","NDPD was beneficially owned by company officers; transaction approved by board as a related-party acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172839,"accession_number":"0001493152-25-003136","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["1.01","8.01","3.02","9.01"],"status":"ready","headline":"Bioxytran secures $1.6M stock purchase with Triton Funds; management forfeits $460K salaries","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Triton Funds LP commits up to $1.6M for up to 17.5M shares (19.9%) at lowest traded price 10 days prior to closing.","Proceeds: $805,000 to extinguish an existing note; balance for pre-clinical/clinical trials and working capital.","Management forfeits more than $460,000 in accrued salaries and expenses to support the transaction.","Closing requires effectiveness of a Form S-1 registration statement to be filed within 7 days; Triton gets $35,000 admin fee.","The deal follows Triton's prior investment; it aims to remove convertible note overhang and fund development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172838,"accession_number":"0001493152-25-001891","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["4.02","9.01"],"status":"ready","headline":"BioXytran restates 2022-2023 financials on share valuation errors; non-reliance on prior filings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss for 2023 increased by $192,523 to $4.56M; for 2022 increased by $9,202 to $2.67M.","Restatement driven by misvaluation of shares under Rule 3(a)(9) and Rule 701, and timing errors in accruals.","Company engaged Fruci & Associates as successor auditor after SEC denied BF Borgers privilege.","Common stock adjusted (1M shares returned to treasury in 2023; 93,750 shares added in 2022).","No net impact on cash flows from operations, investing, or financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172837,"accession_number":"0001493152-25-001603","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran publishes preprint on galectin-3's role in ICI resistance and potential enhancement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preprint reviews theories that galectin-3 contributes to ICI resistance; galectin-3 antagonists may reverse effect.","90% of high galectin-3 NSCLC patients failed to respond to ICI after 3 treatments.","Surface Plasmon Resonance and cryo-EM confirm galectin-3 blocks ICI binding to PD-1 receptor.","Company also published cancer presentation on galectin antagonists in cancer.","CEO states findings herald significant shift in cancer treatment paradigms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189848,"accession_number":"0001493152-24-042741","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bioxytran acquires NDPD Pharma for $15.85M in stock; CFO adopts 10b5-1 plan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of NDPD Pharma for stock: 3.39M common shares at $0.109 and 28.47M preferred shares at $0.543.","NDPD holds patents for ProLectin-M (COVID-19, RSV, H1N1, etc.) and a license agreement valued at $8.19M.","CFO Ola Soderquist adopted 10b5-1 plan to sell up to 500,000 common shares through March 31, 2025.","Consideration includes 14.1M Bioxytran preferred shares returned to treasury with a $4.0M book value.","Goodwill of $5.38M recorded; intangible assets amortized over 18 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206361,"accession_number":"0001493152-24-033314","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["3.03","8.01","9.01"],"status":"ready","headline":"Bioxytran issues 28.97M preferred shares to insiders, converts 94M common shares and $354K debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 28,971,248 convertible preferred shares to insiders in exchange for 94,057,658 common shares at a 5:1 ratio.","Preferred shares have super voting rights: vote on 'as if converted' basis multiplied by 2; insiders now control 77.9% voting power.","Conversion also extinguished $353,840 in accrued salaries, accounts receivable, and short-term debt plus 14.41M subsidiary shares.","Common shares outstanding reduced to 81,850,495; par value $0.001 per share; listed on OTCQB.","Press release announces peer-reviewed British Journal article on carbon monoxide in mitochondria, using MDX Viewer to validate BXT-25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206360,"accession_number":"0001493152-24-028081","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bioxytran launches JV with Heme Foundation for universal oxygen carrier; up to $10M pledged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["JV with Heme Foundation and NDPD Pharma to develop Universal Oxygen Carrier (UOC) as blood substitute.","Heme Foundation pledges up to $10M over project; $2M already invested in prototypes and compounds.","Total development cost estimated $20M-$25M over 3.5 to 5 years; Bioxytran retains IP.","Two successful small animal trials (mice, rabbits) completed; large 14-day toxicology study planned.","UOC compatible with all blood types, shelf-stable 5+ years, 18-hour half-life, no known side effects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206359,"accession_number":"0001493152-24-026269","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran announces Springer book linking hyperbaric oxygenation to BXT-25 drug","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Book by Prof. Mayevsky published by Springer; covers hyperbaric oxygenation and mitochondrial activity.","BXT-25 is an acellular oxygen carrier (AOC) 5,000x smaller than RBC; aims to replace HBOT.","MDX Viewer (FDA-approved) measures tissue oxygenation via Brain Metabolic Score (BMS).","BMS used as biomarker to demonstrate efficacy in upcoming stroke and Alzheimer's trials.","Company expects coupling BXT-25 with MDX Viewer could shorten clinical trial timelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223474,"accession_number":"0001493152-24-018484","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Bioxytran dismisses BF Borgers, appoints Fruci & Associates as new auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dismissed BF Borgers CPA PC as independent auditor effective May 7, 2024.","Appointed Fruci & Associates II, PLLC as new independent accountants.","No disagreements or reportable events occurred during 2022-2023 or through March 31, 2024.","Change was recommended by Audit Committee and approved by Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}